Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone ± thalidomide for systemic light-chain amyloidosis: Results of a phase II trial

British Journal of Haematology

Volumn 139, Issue 2, 2007, Pages 224-233

  Cohen, Adam D ^a   Zhou, Ping ^a   Chou, Joanne ^a   Teruya Feldstein, Julie ^a   Reich, Lilian ^a   Hassoun, Hani ^a   Levine, Beth ^a   Filippa, Daniel A ^a   Riedel, Elyn ^a   Kewalramani, Tarun ^a   Stubblefield, Michael D ^a   Fleisher, Martin ^a   Nimer, Stephen ^a   Comenzo, Raymond L ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Amyloidosis; Clinical trials; Risk adapted melphalan; Stem cell transplantation; Thalidomide

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; COTRIMOXAZOLE; DEXAMETHASONE; DOCUSATE SODIUM; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; PROTON PUMP INHIBITOR; PYRIDOXINE; THALIDOMIDE;

ADULT; AGED; AMYLOID NEUROPATHY; AMYLOIDOSIS; ANXIETY; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE NECROSIS; CELL CLONE; CELL DAMAGE; CELLULITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; DEEP VEIN THROMBOSIS; DRUG DOSE TITRATION; DRUG FATALITY; DRUG WITHDRAWAL; FATIGUE; FEASIBILITY STUDY; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEART AMYLOIDOSIS; HISTORY; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; KIDNEY AMYLOIDOSIS; KIDNEY FUNCTION; LIVER DISEASE; LUNG EMBOLISM; MALE; MANIA; MORTALITY; NUCLEOTIDE SEQUENCE; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PLASMA CELL; PNEUMONIA; PRIORITY JOURNAL; RISK; SIDE EFFECT; SINUSITIS; SURVIVAL RATE; SYSTEMIC LIGHT CHAIN AMYLOIDOSIS; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREATMENT RESPONSE;

ADJUVANTS, IMMUNOLOGIC; ADJUVANTS, PHARMACEUTIC; ADULT; AGED; AMYLOIDOSIS; COMBINED MODALITY THERAPY; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MELPHALAN; MIDDLE AGED; MYELOABLATIVE AGONISTS; PROPORTIONAL HAZARDS MODELS; REMISSION INDUCTION; RISK ASSESSMENT; SURVIVAL RATE; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS;

EID: 34848837980     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2007.06783.x     Document Type: Article

References (42)

1. Attal, M., Harousseau, J.L., Leyvraz, S., Doyen, C., Hulin, C., Benboubker, L., Agha, I.Y., Bourhis, J.H., Garderet, L., Pegourie, B., Dumontet, C., Renaud, M., Voillat, L., Berthou, C., Marit, G., Monconduit, M., Caillot, D., Grobois, B., Avet-Loiseau, H., Moreau, P. Facon, T. (2006) Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood, 108, 3289 3294.
2. Comenzo, R.L. Gertz, M.A. (2002) Autologous stem cell transplantation for primary systemic amyloidosis. Blood, 99, 4276 4282.
3. Comenzo, R.L., Sanchorawala, V., Fisher, C., Akpek, G., Farhat, M., Cerda, S., Berk, J.L., Dember, L.M., Falk, R., Finn, K., Skinner, M. Vosburgh, E. (1999a) Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis. British Journal of Haematology, 104, 553 559.
4. Comenzo, R.L., Wally, J., Kica, G., Murray, J., Ericsson, T., Skinner, M. Zhang, Y. (1999b) Clonal immunoglobulin light chain variable region germline gene use in AL amyloidosis: association with dominant amyloid-related organ involvement and survival after stem cell transplantation. British Journal of Haematology, 106, 744 751.
5. Comenzo, R.L., Zhang, Y., Martinez, C., Osman, K. Herrera, G.A. (2001) The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden. Blood, 98, 714 720.
6. 2) in multiple myeloma patients undergoing autologous stem cell transplantation. Leukemia, 20, 345 349.
7. Dhodapkar, M.V., Hussein, M.A., Rasmussen, E., Solomon, A., Larson, R.A., Crowley, J.J. Barlogie, B. (2004) Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. Blood, 104, 3520 3526.
8. Dispenzieri, A., Lacy, M.Q., Rajkumar, S.V., Geyer, S.M., Witzig, T.E., Fonseca, R., Lust, J.A., Greipp, P.R., Kyle, R.A. Gertz, M.A. (2003) Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid, 10, 257 261.
9. Dispenzieri, A., Kyle, R.A., Lacy, M.Q., Therneau, T.M., Larson, D.R., Plevak, M.F., Rajkumar, S.V., Fonseca, R., Greipp, P.R., Witzig, T.E., Lust, J.A., Zeldenrust, S.R., Snow, D.S., Hayman, S.R., Litzow, M.R., Gastineau, D.A., Tefferi, A., Inwards, D.J., Micallef, I.N., Ansell, S.M., Porrata, L.F., Elliott, M.A. Gertz, M.A. (2004a) Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood, 103, 3960 3963.
10. Dispenzieri, A., Gertz, M.A., Kyle, R.A., Lacy, M.Q., Burritt, M.F., Therneau, T.M., Greipp, P.R., Witzig, T.E., Lust, J.A., Rajkumar, S.V., Fonseca, R., Zeldenrust, S.R., McGregor, C.G. Jaffe, A.S. (2004b) Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. Journal of Clinical Oncology, 22, 3751 3757.
11. Dispenzieri, A., Gertz, M.A., Kyle, R.A., Lacy, M.Q., Burritt, M.F., Therneau, T.M., McConnell, J.P., Litzow, M.R., Gastineau, D.A., Tefferi, A., Inwards, D.J., Micallef, I.N., Ansell, S.M., Porrata, L.F., Elliott, M.A., Hogan, W.J., Rajkumar, S.V., Fonseca, R., Greipp, P.R., Witzig, T.E., Lust, J.A., Zeldenrust, S.R., Snow, D.S., Hayman, S.R., McGregor, C.G. Jaffe, A.S. (2004c) Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood, 104, 1881 1887.
12. Dispenzieri, A., Lacy, M.Q., Katzmann, J.A., Rajkumar, S.V., Abraham, R.S., Hayman, S.R., Kumar, S.K., Clark, R., Kyle, R.A., Litzow, M.R., Inwards, D.J., Ansell, S.M., Micallef, I.M., Porrata, L.F., Elliott, M.A., Johnston, P.B., Greipp, P.R., Witzig, T.E., Zeldenrust, S.R., Russell, S.J., Gastineau, D. Gertz, M.A. (2006) Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood, 107, 3378 3383.
13. Dispenzieri, A., Lacy, M.Q., Zeldenrust, S.R., Hayman, S.R., Kumar, S.K., Geyer, S.M., Lust, J.A., Allred, J.B., Witzig, T.E., Rajkumar, S.V., Greipp, P.R., Russell, S.J., Kabat, B. Gertz, M.A. (2007) The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood, 109, 465 470.
14. Gertz, M.A. Kyle, R.A. (1990) Acute leukemia and cytogenetic abnormalities complicating melphalan treatment of primary systemic amyloidosis. Archives of Internal Medicine, 150, 629 633.
15. Gertz, M.A., Blood, E., Vesole, D.H., Abonour, R., Lazarus, H.M. Greipp, P.R. (2004a) A multicenter phase 2 trial of stem cell transplantation for immunoglobulin light-chain amyloidosis (E4A97): an Eastern Cooperative Oncology Group Study. Bone Marrow Transplantation, 34, 149 154.
16. Gertz, M.A., Lacy, M.Q., Dispenzieri, A., Ansell, S.M., Elliott, M.A., Gastineau, D.A., Inwards, D.J., Micallef, I.N., Porrata, L.F., Tefferi, A. Litzow, M.R. (2004b) Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplantation, 34, 1025 1031.
17. Gertz, M.A., Comenzo, R., Falk, R.H., Fermand, J.P., Hazenberg, B.P., Hawkins, P.N., Merlini, G., Moreau, P., Ronco, P., Sanchorawala, V., Sezer, O., Solomon, A. Grateau, G. (2005) Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. American Journal of Hematology, 79, 319 328.
18. Gertz, M.A., Lacy, M.Q., Dispenzieri, A., Hayman, S.R. Kumar, S. (2007) Transplantation for amyloidosis. Current Opinion in Oncology, 19, 136 141.
19. Giudicelli, V., Duroux, P., Ginestoux, C., Folch, G., Jabado-Michaloud, J., Chaume, D. Lefranc, M.P. (2006) IMGT/LIGM-DB, the IMGT comprehensive database of immunoglobulin and T cell receptor nucleotide sequences. Nucleic Acids Research, 34, D781 D784.
20. Hideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F.E., Tai, Y.T., Treon, S.P., Lin, B., Schlossman, R.L., Richardson, P., Muller, G., Stirling, D.I. Anderson, K.C. (2000) Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood, 96, 2943 2950.
21. Jaccard, A., Moreau, P., V, L., Leleu, X., Benboubker, L., Hermine, O., Recher, C., Malphette, M., Lioure, B., Royer, B., Grosbois, B., Jaubert, J., Preux, P.M., Cogne, M. Fermand, J.P. (2005) Autologous stem cell transplantation (ASCT) versus oral melphalan and high-dose dexamethasone in patients with AL (Primary) amyloidosis: results of the French multicentric randomized trial (MAG and IFM Intergroup). Blood, 106, 127a.
22. Kyle, R.A., Gertz, M.A., Greipp, P.R., Witzig, T.E., Lust, J.A., Lacy, M.Q. Therneau, T.M. (1997) A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. New England Journal of Medicine, 336, 1202 1207.
23. Lachmann, H.J., Booth, D.R., Booth, S.E., Bybee, A., Gilbertson, J.A., Gillmore, J.D., Pepys, M.B. Hawkins, P.N. (2002) Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. New England Journal of Medicine, 346, 1786 1791.
24. Lachmann, H.J., Gallimore, R., Gillmore, J.D., Carr-Smith, H.D., Bradwell, A.R., Pepys, M.B. Hawkins, P.N. (2003) Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. British Journal of Haematology, 122, 78 84.
25. Leung, N., Leung, T.R., Cha, S.S., Dispenzieri, A., Lacy, M.Q. Gertz, M.A. (2005) Excessive fluid accumulation during stem cell mobilization: a novel prognostic factor of first-year survival after stem cell transplantation in AL amyloidosis patients. Blood, 106, 3353 3357.
26. Moskowitz, C.H., Kewalramani, T., Nimer, S.D., Gonzalez, M., Zelenetz, A.D. Yahalom, J. (2004) Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. British Journal of Haematology, 124, 645 652.
27. Palladini, G., Campana, C., Klersy, C., Balduini, A., Vadacca, G., Perfetti, V., Perlini, S., Obici, L., Ascari, E., d'Eril, G.M., Moratti, R. Merlini, G. (2003) Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation, 107, 2440 2445.
28. Palladini, G., Perfetti, V., Obici, L., Caccialanza, R., Semino, A., Adami, F., Cavallero, G., Rustichelli, R., Virga, G. Merlini, G. (2004) Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood, 103, 2936 2938.
29. Palladini, G., Perfetti, V., Perlini, S., Obici, L., Lavatelli, F., Caccialanza, R., Invernizzi, R., Comotti, B. Merlini, G. (2005) The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood, 105, 2949 2951.
30. Palladini, G., Lavatelli, F., Russo, P., Perlini, S., Perfetti, V., Bosoni, T., Obici, L., Bradwell, A.R., D'Eril, G.M., Fogari, R., Moratti, R. Merlini, G. (2006) Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood, 107, 3854 3858.
31. Perfetti, V., Siena, S., Palladini, G., Bregni, M., Di Nicola, M., Obici, L., Magni, M., Brunetti, L., Gianni, A.M. Merlini, G. (2006) Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis. Haematologica, 91, 1635 1643.
32. Rajkumar, S.V., Blood, E., Vesole, D., Fonseca, R. Greipp, P.R. (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 24, 431 436.
33. Sanchorawala, V., Wright, D.G., Seldin, D.C., Falk, R.H., Finn, K.T., Dember, L.M., Berk, J.L., Quillen, K., Anderson, J.J., Comenzo, R.L. Skinner, M. (2004) High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. Bone Marrow Transplantation, 33, 381 388.
34. Sanchorawala, V., Seldin, D.C., Magnani, B., Skinner, M. Wright, D.G. (2005) Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transplantation, 36, 597 600.
35. Sanchorawala, V., Wright, D.G., Rosenzweig, M., Finn, K.T., Fennessey, S., Zeldis, J.B., Skinner, M. Seldin, D.C. (2007) Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood, 109, 492 496.
36. Seldin, D.C., Choufani, E.B., Dember, L.M., Wiesman, J.F., Berk, J.L., Falk, R.H., O'Hara, C., Fennessey, S., Finn, K.T., Wright, D.G., Skinner, M. Sanchorawala, V. (2003) Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. Clinical Lymphoma, 3, 241 246.
37. Seldin, D.C., Anderson, J.J., Sanchorawala, V., Malek, K., Wright, D.G., Quillen, K., Finn, K.T., Berk, J.L., Dember, L.M., Falk, R.H. Skinner, M. (2004) Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. Blood, 104, 1888 1893.
38. Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeddis, J. Barlogie, B. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. New England Journal of Medicine, 341, 1565 1571.
39. Skinner, M., Anderson, J., Simms, R., Falk, R., Wang, M., Libbey, C., Jones, L.A. Cohen, A.S. (1996) Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. American Journal of Medicine, 100, 290 298.
40. Skinner, M., Sanchorawala, V., Seldin, D.C., Dember, L.M., Falk, R.H., Berk, J.L., Anderson, J.J., O'Hara, C., Finn, K.T., Libbey, C.A., Wiesman, J., Quillen, K., Swan, N. Wright, D.G. (2004) High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Annals of Internal Medicine, 140, 85 93.
41. Wechalekar, A.D., Goodman, H.J., Lachmann, H.J., Offer, M., Hawkins, P.N. Gillmore, J.D. (2007) Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood, 109, 457 464.
42. Zhou, P., Olshen, A.B., Teruya-Feldstein, J. Comenzo, R. (2006) Increased calreticulin expression in clonal plasma cells is associated with complete response to melphalan and autologous stem cell transplant in systemic light-chain amyloidosis. Blood, 108, 3096a.